EX-105

N/A

Report date: 2026/03/19 17:01:21

Base Information

Drug NameEX-105

Drug Alias NameEX-105EX105

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsAnti-CD3 +[4]

TargetsT cell surface glycoprotein CD3CD276 antigen

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesGuangzhou Excelmab Inc

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGuangzhou Excelmab Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A